Non-Hodgkin Lymphoma in the Middle East Is Characterized by Low Incidence Rates With Advancing Age

Rafil T. Yaqo, MBChB; Sana D. Jalal, MBChB; Kharaman J. Ghafour, MBChB; Hemin A. Hassan, MBChB; and Michael D. Hughson, MD

Abstract

PURPOSE In the Middle East, incidence rate ratios (IRRs) of non-Hodgkin lymphoma (NHL) to Hodgkin lymphoma (HL) are more than 50% lower than the United States.

MATERIALS AND METHODS Age-specific incidence rates (ASIRs), age-adjusted incidence rates (AAIRs), and IRRs of NHL:HL were compared using the cancer registries of Iraq, Jordan, Saudi Arabia, and US SEER.

RESULTS The NHL AAIR (95% CI) per 100,000 population was 4.4 (4.1 to 4.7) for Iraq, 5.4 (4.6 to 6.2) for Jordan, 4.7 (4.4 to 5.1) for Saudi Arabia, and 13.2 (13.0 to 13.4) for the United States. The HL AAIR was 1.8 (1.6 to 2.0) for Iraq, 1.8 (1.4 to 2.2) for Jordan, 2.1 (1.9 to 2.2) for Saudi Arabia, and 2.3 (2.2 to 2.4) for the United States, with respective NHL:HL IRR of 2.4 (2.2 to 2.7), 3.0 (2.4 to 3.8), 2.2 (2.0 to 2.5), and 5.7 (5.5 to 6.0). NHL ASIRs for the Middle East and the United States were similar until 30 to 39 years of age. Thereafter, ASIR of NHL peaked at 20 to 33 per 100,000 at age 70 years in the Middle East regions, all much lower than the US age 70 years rate of greater than 100 per 100,000. Diffuse large B-cell lymphoma (DLBCL) represented 52% of NHL in Sulaimaniyah Province of Iraq and 51% of NHL in Saudi Arabia. Both regions had AAIR for DLBCL less than 42% of DLBCL in US SEER. Pediatric Epstein-Barr virus–related Burkitt’s lymphoma at 8% was the second most frequent NHL in Sulaimaniyah but made little contribution to overall NHL rates.

CONCLUSION The incidence of HL was slightly lower than in the United States, but it was the markedly lower rates of adult NHL with advancing age, including the predominant DLBCL, that accounted for the low NHL:HL IRR in these Middle Eastern countries.

J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

provides central pathology review for Hiwa Hospital patients. Data were obtained from Hiwa Hospital and Sharsh Pathology Department for patients registered between January 1, 2010 and December 31, 2014 as residents of Sulaimaniyah Province. Iraq data were obtained from the 2010 Iraqi Cancer Registry,1 Jordanian data from the 2012 Jordan Cancer Registry,2 Saudi Arabian data from the 2014 Saudi Arabia Cancer Registry,3,4 and US data from the SEER Cancer Statistic Review, 1975 to 2014.9

**EBV-encoded small RNAs (EBER1 and EBER2).**

System; ZytoVision, Bremerhaven, Germany for HL) against systems, Wetzler, Germany for BL and ZytoFast EBV-CISH hybridization using the probes (Novocastra; Leica Bio-

Epstein-Barr virus (EBV) latency was assessed by in situ

Translocation in BL

Epstein-Barr Virus in HL and Epstein-Barr Virus and MYC Translocation in BL

Epstein-Barr virus (EBV) latency was assessed by in situ hybridization using the probes (Novocastra; Leica Biosystems, Wetzler, Germany for BL and ZytoFast EBV-CISH system; ZytoVision, Bremerhaven, Germany for HL) against EBV-encoded small RNAs (EBER1 and EBER2). C-MYC/IGH translocations were analyzed by fluorescence in situ hybridization using a break-apart probe (Vysis MYC; Abbott, Abbott Park, IL). The studies used formalin-fixed, paraffin-embedded tissue on 22 BLs and 33 HLs.

**Data Analysis**

Data were entered into Excel worksheets and analyzed with Excel mathematical functions or Stata IC10 (STATA, College Station, TX) statistical software. Uncertainty was analyzed by comparing 95% CIs for ASIR, AAIR, and IRR in the different geographic regions. The calculation of CI was based on the following formulas for directly age-adjusted rates12 and rate ratios13:

\[
95\% \text{ CI}(\text{ASIR}) = 1.96 \times \left( \sqrt{\frac{R^2}{Ni}} \right)
\]

where \( R = \) age-specific incidence in the 10-year age group, and \( Ni = \) number of tumors in the age-specific age group.

\[
95\% \text{ CI}(\text{AAIR}) = 1.96 \times SE(\text{standard error}) \times AAIR where
\]

\[
\text{AAIR var (variance)} = \sum Wsi \times R^2 / Niard
\]

\[
\text{SE(\text{AAIR})} = \sqrt{\frac{\text{AAIR var}}{Ni}}
\]

where \( Wsi = \) weight in the standard population of the 10-year age group.

95% CI (IRR) = antilog (e) of lower and upper bounds of the natural log of the IRR,

\[
\log IRR = \frac{1}{\sqrt{1/N1 + 1/N2}}
\]

\[
\text{Lower bound} = \log IRR - 1.96 \times \sqrt{1/N1 + 1/N2}
\]

\[
\text{Upper bound} = \log IRR + 1.96 \times \sqrt{1/N1 + 1/N2}
\]

where \( N1 = \) number of lymphomas for population 1, and \( N2 = \) number of lymphomas for population 2.

Differences were considered significant if the 95% CI did not overlap. For HL, a ratio of ASIRs and AAIRs for Iraq, Jordan, and the United States were indexed to Saudi Arabia. The differences in IRR were considered significantly different than Saudi Arabia if the 95% CI did not include 1.

**RESULTS**

Lymphoma Subtypes

In the 5-year period 2010 to 2014, 128 cases of HL and 406 cases of NHL were diagnosed in the Sulaimaniyah
Table 1 provides the distribution of the total populations and the number of NHLs and HLs in 10-year intervals for Sulaimaniyah, Iraq, Jordan, Saudi Arabia, and US SEER. All of the Middle East regions have a young age structure, with 75% to 82% of the populations being younger than 40 years old.

Male to female IRRs were nearly the same for both NHL and HL in each region except HL in Jordan, where more females were recorded than males (Table 3). This was a seemingly aberrant 1-year occurrence; previous multiyear Jordanian studies have shown a 1.4:1 male to female HL ratio. We do not believe that there are any significant regional sex differences, and subsequent analyses were for total populations. The ASIRs of each region are shown for NHL (Table 4) and HL (Table 5) together with the AAIR and the 95% CI for each calculation.

For NHL, the 95% CIs of the AAIRs for each of the Middle East regions overlapped with each other, as did the 95% CIs of the ASIRs for each of the 10-year intervals (except for the 70 years or older group between Iraq and Saudi Arabia). We interpret these findings as indicating that there are no significant differences in the 10-year ASIR or the AAIR between the Middle Eastern regions for NHL. The NHL 10-year age-specific rates for the United States began to diverge from those of the Middle East at approximately 30 years of age, by age 60 years doubled, and after age 70 years more than tripled Middle Eastern rates (Fig 1).

For HL, the AAIRs were similar for Iraq, Jordan, and Saudi Arabia. In all of the Middle East registries, most HL was found in those younger than 40 years of age (73% in Iraq; 78% in Jordan and Saudi Arabia), whereas in US SEER, 50% of HL was diagnosed after 39 years of age. Jordan and the country of Iraq had attenuated late peaks compared with the United States, and Saudi Arabia had a late peak that matched the United States at 70 years of age or older.

HL rates for Sulaimaniyah were low and changed little after 40 years of age, but the low numbers and the wide 95% CI precluded any regional comparisons. Regional comparisons, therefore, used only national data indexed as an IRR to Saudi Arabia. Saudi Arabia was chosen as the index, because it had the IARC-affiliated registry with the largest number of cases. These comparisons are shown as a Forest plot in Figure 2 (Data Supplement). The HL IRR of the United States was markedly lower than Saudi Arabia at 0 to 9 years of age but was significantly higher from 20 to 50 years of age. The indexed AAIR showed no significant

Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; IQR, interquartile range; MALT, mucosal-associated lymphoid tissue; MF, mycosis fungoides; MZL, marginal zone lymphoma; NA, not applicable; NHL, non-Hodgkin lymphoma; NK, natural killer; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma.
TABLE 2. Regional Populations and Annual Number of NHLs and HLs for the Designated Years

| Age (years) | Sulaimaniyah 2012 | Iraq 2010 | Jordan 2012 | Saudi Arabia 2014 | US SEER 2006-2011 |
|-------------|-------------------|-----------|-------------|-------------------|-------------------|
|             | Pop   | NHL | HL | Pop   | NHL | HL | Pop   | NHL | HL | Pop   | NHL | HL | Pop   | NHL | HL |
| 0-9         | 4.22  | 7.2 | 2.4 | 91.78 | 132 | 53 | 16.18 | 10  | 7  | 41.41 | 29  | 37 | 138   | 131 | 34 |
| 10-19       | 4.17  | 5.6 | 6.8 | 75.51 | 62  | 87 | 14.63 | 8   | 29 | 35.55 | 51  | 104| 134   | 222 | 279|
| 20-29       | 3.63  | 8.2 | 6.0 | 54.94 | 87  | 148| 12.47 | 15  | 28 | 38.10 | 78  | 118| 141   | 416 | 571|
| 30-39       | 2.78  | 9.4 | 6.2 | 41.07 | 102 | 85 | 9.05  | 32  | 19 | 31.51 | 78  | 60 | 130   | 755 | 410|
| 40-49       | 2.07  | 10.4| 2.0 | 29.86 | 121 | 50 | 5.16  | 36  | 7  | 22.67 | 90  | 28 | 142   | 1,718 | 362|
| 50-59       | 1.15  | 12.0| 0.8 | 16.75 | 188 | 42 | 3.03  | 35  | 12 | 14.52 | 125 | 31 | 135   | 3,463 | 331|
| 60-69       | 0.72  | 17.0| 0.8 | 9.20  | 148 | 31 | 2.14  | 43  | 2  | 7.59  | 121 | 12 | 93    | 4,865 | 263|
| ≥ 70        | 0.57  | 11.4| 0.6 | 5.79  | 112 | 18 | 1.21  | 38  | 3  | 5.20  | 173 | 21 | 87    | 8,883 | 351|
| Total       | 19.31 | 81.2| 25.6| 324.90| 952 | 514| 63.88 | 217 | 107| 196.55| 745 | 411| 1,000 | 20,403 | 2,601|

NOTE. Populations are listed as number \times 100,000. NHL and HL are the numbers of lymphomas diagnosed in the indicated years, with Sulaimaniyah being the average of the 5-year period 2010 to 2014. The numbers of lymphomas in US SEER are an annual average for the years 2006 to 2011 extrapolated to a population of 100 million persons.

Abbreviations: HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; Pop, population.
differences in total rates of HL between Saudi Arabia and Iraq, Jordan, or the United States.

**Comparison of NHL:HL IRRs**

The NHL:HL IRR (95% CI) for Iraq at 2.4 (2.2 to 2.7), Jordan at 3.0 (2.4 to 3.8), and Saudi Arabia at 2.2 (2.0 to 2.5) were similar to each other and significantly lower than the US rate at 5.7 (5.5 to 6.0; Table 6). The Sulaimaniyah rate of 4.2 (2.7 to 6.5) was not significantly different from the United States at 5.7 (5.5 to 6.0) or the other Middle East regions, with this overlap reflecting the small Sulaimaniyah HL sample size and its wide 95% CI.

**DLBCL in Sulaimaniyah and Estimates for Saudi Arabia**

DLBCL represented 52% of NHL in Sulaimaniyah, with an AAIR of 2.9 per 100,000. DLBCL represented 51% of NHL in Saudi Arabia. If it is assumed that these DLBCLs had the same age distribution as Sulaimaniyah, the Saudi Arabia AAIR was 2.6 per 100,000. In the United States, the AAIR for DLBCL was 6.9 per 100,000, a factor 2.4 times greater than Sulaimaniyah or Saudi Arabia. The ASIR for DLBCL in Sulaimaniyah peaked at 13.3 per 100,000 persons at 60 to 69 years old, whereas in the United States, the ASIR of DLBCL was 33.5 per 100,000 after 65 years of age.9

**BL Sulaimaniyah**

NHLs in Sulaimaniyah, with childhood defined as age 19 years or younger, are presented in Table 7. BL represented 75% of all childhood NHL in those younger than 10 years of age, with 68% being intestinal. The annual incidence of BL was 16.7 per million children for males and 2.5 per million for females.

**EBV EBER and C-MCY Translocations in BL and EBV EBER in HL**

All BLs were positive for C-MYC/IGH translocations, and 20 of the 22 cases showed positive nuclear staining for EBER. The two negative EBER cases were not tested for RNA integrity. Four of nine mixed-cellularity HLs (44%), six of 24 nodular sclerosis (25%), and a total of 30% of HLs were EBER positive. The difference in the HL subtype proportions was not significant (Fisher exact test, \( P = .23 \)), nor was the age difference of patients with HL by EBV status significant (EBV-positive, 28.1 ± 21.1 years; EBV-negative, 36.0 ± 19.9 years; \( P = .31 \)).

**DISCUSSION**

In this study, the IRRs (95% CI) of NHL:HL in Iraq of 2.4 (2.2 to 2.7), Jordan at 3.0 (2.4 to 3.8), and Saudi Arabia at 2.2 (2.0 to 2.5) were similar to each other and significantly lower than the United States at 5.7 (5.5 to 6.0).3,4,9 It is further shown that the low Middle Eastern IRRs were the result of a relative infrequency of NHL in late middle age and the elderly. Until early adulthood, the ASIRs of NHL from the Middle East and the United States were nearly identical, and it was just before 40 years of age that US NHL rates began to increase above and after age 70 years to nearly triple Middle Eastern rates.9

The lower incidence of NHL in the Middle East can be partly attributed to the low frequency of follicular lymphoma.15,16

| NHL | Sulaimaniyah | Iraq | Jordan | Saudi Arabia | US SEER |
|-----|--------------|------|--------|--------------|--------|
|     | 1.5 (1.0 to 2.3) | 1.3 (1.1 to 1.5) | 1.3 (1.0 to 1.7) | 1.4 (1.2 to 1.6) | 1.4 (1.37 to 1.43) |
| HL  | 1.3 (0.6 to 2.9)  | 1.3 (1.1 to 1.5) | 0.8 (0.5 to 1.2)* | 1.3 (1.1 to 1.6) | 1.2 (1.14 to 1.27) |

*The IRR male:female for Jordanian HL is aberrantly low (see Results).
| Age (years) | Sulaimaniyah | Iraq | Jordan | Saudi Arabia | US SEER |
|------------|-------------|------|--------|--------------|--------|
|            | ASIR        | 95% CI | ASIR   | 95% CI       | ASIR   | 95% CI | ASIR   | 95% CI       | ASIR   | 95% CI | ASIR   | 95% CI       | ASIR   | 95% CI |
| 0-9        | 0.6         | -0.2 to 1.4 | 0.6    | 0.4 to 0.8   | 0.4    | 0.1 to 0.7 | 0.9    | 0.6 to 1.2   | 0.2    | 0.1 to 0.3 |
| 10-19      | 1.6         | 0.4 to 2.8 | 1.2    | 0.9 to 1.5   | 2.0    | 1.3 to 1.7 | 2.9    | 2.3 to 3.5   | 2.1    | 1.9 to 2.3 |
| 20-29      | 1.7         | 0.3 to 3.1 | 2.7    | 2.3 to 3.1   | 2.2    | 1.4 to 3.0 | 3.1    | 2.5 to 3.7   | 4.0    | 3.7 to 4.3 |
| 30-39      | 2.2         | 0.5 to 3.9 | 2.1    | 1.7 to 2.5   | 2.1    | 1.2 to 3.0 | 1.9    | 1.4 to 2.4   | 3.2    | 2.9 to 3.5 |
| 40-49      | 1.0         | -0.4 to 2.4 | 1.7    | 1.2 to 2.2   | 1.4    | 0.4 to 2.4 | 1.2    | 0.7 to 1.7   | 2.5    | 2.2 to 2.8 |
| 50-59      | 0.7         | -0.8 to 2.2 | 2.5    | 1.7 to 3.3   | 4.0    | 1.7 to 6.3 | 2.1    | 1.4 to 2.8   | 2.5    | 2.2 to 2.8 |
| 60-69      | 1.1         | -1.3 to 3.5 | 3.4    | 2.2 to 4.6   | 0.9    | -0.3 to 2.1 | 1.6    | 0.7 to 2.5   | 2.8    | 2.5 to 3.1 |
| ≥ 70       | 1.1         | -1.7 to 3.9 | 3.1    | 1.7 to 4.5   | 2.5    | -0.3 to 5.3 | 4.0    | 2.3 to 5.7   | 4.0    | 3.6 to 4.4 |
| AAIR       | 1.3         | 0.8 to 1.8 | 1.8    | 1.6 to 2.0   | 1.8    | 1.4 to 2.2 | 2.1    | 1.9 to 2.1   | 2.3    | 2.2 to 2.4 |

Abbreviations: AAIR, age-adjusted incidence rate; ASIR, age-specific incidence rate.
Nevertheless, an AAIR less than 42% of the US rate was estimated for DLBCL in Sulaimaniyah and Saudi Arabia, which at diagnostic frequencies of 52% and 51% were by far the most common NHL in these regions, with a 56% frequency of DLBCL being reported from Jordan. In the United States, a 2.3 times higher AAIR of DLBCL compared with the Middle East comes at a lower diagnostic frequency of 22% among US SEER NHL, emphasizing that diagnostic frequency and disease incidence are unrelated. 

![Graph of age-specific incidence rate (ASIR) with increasing age.](image1)

**FIG 1.** Non-Hodgkin lymphoma. Changes in age-specific incidence rate (ASIR) with increasing age. ASIR is similar in all regions until approximately age 30 years, when US rates begin to increase. At 70 years of age and older, US rates are nearly three times those of the Middle East, where the small differences are not significant. Black, Sulaimaniyah; blue, Iraq; purple, Jordan; teal, Saudi Arabia; dark orange, United States.

![Graph of incidence rate ratios (IRRs) of Iraq (I), Jordan (J), and US Hodgkin lymphoma age-specific and age-adjusted incidence rates (AAIRs) indexed to Saudi Arabia.](image2)

**FIG 2.** Incidence rate ratios (IRRs) of Iraq (I), Jordan (J), and US Hodgkin lymphoma age-specific and age-adjusted incidence rates (AAIRs) indexed to Saudi Arabia. Saudi Arabia is represented by an incidence rate = 1. The solid squares represent the IRR and the bars the 95% CIs for the IRR. Age-specific incidence rates are indicated by the age ranges. AAIRs are represented by the top three IRRs.
The indexing of HL rates to Saudi Arabia showed no significant difference in AAIR (95% CI) between Saudi Arabia (1.0), Iraq at 0.9 (0.8 to 1.0), Jordan at 0.9 (0.7 to 1.1), or the United States at 1.1 (1.0 to 1.2). All of the Middle East regions had late age peaks, but more than 70% to 75% of the HL was found before 40 years of age, whereas in the United States, 50% of HL was diagnosed after 39 years of age. It seems notable that the slightly higher rate of HL in the United States compared with the Middle East was not the result of late age peaks but rather of a generally increased rate of HL from 30 to 60 years of age. It is also notable that until 10 years of age, the incidence of HL was markedly lower in the United States compared with Iraq or Saudi Arabia, a likely reflection of the known low rates of HL in young children of the United States.18

Childhood rates for NHL were similar to that reported from US SEER, with the exception of BL. This BL is common in many Middle Eastern countries17-20 but may be half as frequent in Saudi Arabia at 4% of NHL as in Sulaimaniyah and Jordan at 8%.8,17 It has a marked male predominance, usually arises in the terminal ileum, and contains EBV genomic material in nearly all tumors.19-21 The estimated incidence of BL at 16.7 per million male children in Sulaimaniyah was more than four times greater than the 3.8 per million males reported for US patients in the pediatric registry of the IARC but considerably less than rates of endemic BL from Uganda at 30.0/million males.18 Whether the BL of the Middle East is sporadic or endemic is uncertain and probably lies somewhere in between.19

If high rates of BL are related to EBV exposure in young children, this is a curiosity, because early EBV exposure in underdeveloped countries has been associated with childhood mixed-cellularity HL, whereas the later exposure seen in developed countries is associated with adolescent and adult nodular sclerosis.21,22 In Iraq, there has been a shift over the past decades from a predominance of mixed-cellularity to nodular sclerosis 11,23. This may indicate a change in EBV exposure that is affecting HL but not BL.

Nodular sclerosis represents 58% of HL in Saudi Arabia and Jordan and more than 70% of HL in Northern Iraq.8,11,23,24 We found that 30% of Iraqi HLs expressed EBV RNA, a proportion similar to that of non–HIV-infected patients in the United States.25 Nodular lymphocyte–predominant HL that contains EBV RNA in only 3% to 5% of cases26 is reported as 7% to 11% of HL in Saudi Arabia and Jordan. In the United States, nodular lymphocyte–predominant HL comprises approximately 10% and nodular sclerosis 70% of HL, making the Middle Eastern and US patterns of HL subtypes and EBV expression comparable.25

The low rates of NHL in the elderly of Middle East may seem peculiar but are also seen with other cancers.5,6 The similarity of the NHL rates in Iraq, Jordan, and Saudi Arabia indicates a region-wide phenomenon, and it is unlikely that undue numbers of lymphomas are being undiagnosed at any age.

We suggest that an age cohort effect may be occurring in which high noncancer deaths in older members of Middle East populations reduce their risk of NHL.9,27 Life expectancy and the proportion of persons older than 64 years is 69.8 years and 1.8% in Iraq, 74.3 years and 3.3% in Jordan, 74.8 years and 4.1% in Saudi Arabia, and 78.5 years and 14.1% in the United States (Table 8).1,2,8,27,28 The Middle East elderly have high age-specific coronary artery disease death rates and correspondingly low cancer incidence rates (Data Supplement).27 This implies that coronary artery disease deaths beginning at approximately 45 to 55 years of age may diminish the numbers of older survivors who might develop lymphoma.27,29

Of factors that may contribute to lymphoma development in the Middle East, Helicobacter pylori is found in a large

### Table 6. Incidence Rate Ratios of Non-Hodgkin Lymphoma to Hodgkin Lymphoma (with 95% CIs) for the Different Regions

| Subtype of Lymphoma | No. of Patients | Male Frequency | Age (years), Median (IQR) |
|---------------------|----------------|---------------|---------------------------|
| Burkitt’s lymphoma  |                |               |                           |
| < 10 years          | 27             | 0.89          | 5 (4-6)                   |
| ≥ 10 years          | 4              | 0.75          | 12 (11-13)                |
| DLBCL               |                |               |                           |
| < 10 years          | 4              | 0.75          | 4 (3-5)                   |
| ≥ 10 years          | 7              | 0.86          | 17 (15-19)                |
| B-lymphoblastic     |                |               |                           |
| < 10 years          | 3              | 0.66          | 2, 4, 6                   |
| ≥ 10 years          | 4              | 0.75          | 15 (13-18)                |
| T-lymphoblastic     |                |               |                           |
| ≥ 10 years          | 5              | 0.60          | 15 (13-17)                |
| ALCL                |                |               |                           |
| < 10 years          | 2, 2 ALK-positive | 0.50      | 5, 7                      |
| ≥ 10 years          | 6, 5 ALK-positive | 0.83      | 16 (14-17)                |
| Total               | 62             |               |                           |

NOTE. Annual incidence per million children: Burkitt’s lymphoma: all 9.6, male 16.7, female 2.5. Non-Hodgkin lymphoma: all 15.2, male 23.0, female 7.7.

Abbreviations: ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; DLBCL, diffuse large B-cell lymphoma; IQR, interquartile range.

### Table 7. Childhood Non-Hodgkin Lymphoma (age ≤ 19 years) in Sulaimaniyah Province, 2010 to 2014

| Subtype of Lymphoma | No. of Patients | Male Frequency | Age (years), Median (IQR) |
|---------------------|----------------|---------------|---------------------------|
| Burkitt’s lymphoma  |                |               |                           |
| < 10 years          | 27             | 0.89          | 5 (4-6)                   |
| ≥ 10 years          | 4              | 0.75          | 12 (11-13)                |
| DLBCL               |                |               |                           |
| < 10 years          | 4              | 0.75          | 4 (3-5)                   |
| ≥ 10 years          | 7              | 0.86          | 17 (15-19)                |
| B-lymphoblastic     |                |               |                           |
| < 10 years          | 3              | 0.66          | 2, 4, 6                   |
| ≥ 10 years          | 4              | 0.75          | 15 (13-18)                |
| T-lymphoblastic     |                |               |                           |
| ≥ 10 years          | 5              | 0.60          | 15 (13-17)                |
| ALCL                |                |               |                           |
| < 10 years          | 2, 2 ALK-positive | 0.50      | 5, 7                      |
| ≥ 10 years          | 6, 5 ALK-positive | 0.83      | 16 (14-17)                |
| Total               | 62             |               |                           |
majority of adults, EBV is acquired almost universally in childhood, rates of human herpesvirus-8 and hepatitis B and C are low, and autoimmune disease seems to occur at a frequency similar to American whites (Data Supplement).30-39 Only EBV seems to contribute to lymphoma rates, and that to childhood BL. Despite the high prevalence of *H pylori* infection in Iraq, mucosal-associated lymphoid tissue lymphomas are rare and not notably different than in US SEER.9

It is estimated that cancer will increase by 70% in the developing world in the next 25 to 30 years.30 This is projected because populations worldwide are aging, and cancer is largely a disease of the aged. HL in the Middle East may already be in a transitional phase, with nodular sclerosis exceeding mixed cellularity subtypes and with AAIRs approaching that of the United States. As the Middle East becomes more generally affluent, NHL could follow a transition toward higher incidence rates in older members of the population, such as was seen in US SEER in the 20 years between 1977 and 2013.9 Alternatively, current rates could remain low and reflect a genuine variability in NHL oncogenesis.

### AFFILIATIONS
1 Duhuk University School of Medicine, Dohuk, Iraq
2 Sulaimania University College of Medicine, Sulaimaniyah, Iraq
3 Shorsh General and Hiwa Cancer Hospitals, Sulaimaniyah, Iraq

### CORRESPONDING AUTHOR
Michael D. Hughson, MD, Shorsh General Hospital, Qirqa Rd, Sulaimaniyah, Iraq; e-mail: mhughson@bellsouth.net.

### SUPPORT
Supported by the Ministry of Health of the Kurdistan Regional Government.

### AUTHOR CONTRIBUTIONS
Conception and design: Rafil T. Yaqo, Hemin A. Hassan, Michael D. Hughson
Financial support: Rafil T. Yaqo, Hemin A. Hassan
Administrative support: Hemin A. Hassan

### REFERENCES
1. Iraqi Cancer Board, Results of the Iraqi Cancer Registry 2010. Baghdad Iraq: Iraqi Cancer Registry Center, Ministry Of Health 2012.
2. Al-Sayaideh A, Nimri O, Arqoub K, et al: Cancer Incidence in Jordan 2012. Jordan Cancer Registry, 16th report. The Hashimite Kingdom of Jordan Ministry of Health, 2012
3. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
4. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990- to 2015. A systematic analysis for the global burden of disease study. JAMA Oncol 3:524-548, 2017

### TABLE 8. Life Expectancy and Leading Causes of Death in Iraq, Jordan, and Saudi Arabia Compared With the United States

| Variable                     | Iraq          | Jordan       | Saudi Arabia | United States |
|------------------------------|---------------|--------------|--------------|---------------|
| Life expectancy, years       | 69.8          | 74.3         | 74.8         | 78.5          |
| Population > 64 years (%)    | 1.8           | 3.3          | 4.1          | 14.1          |
| Cause of death, incidence (%)|               |              |              |               |
| Coronary disease             | 216.0 (18.5)  | 136.0 (19.8) | 174.2 (24.3) | 86.9 (20.9)   |
| Stroke                       | 94.3 (8.1)    | 77.9 (10.8)  | 89.8 (11.7)  | 23.7 (5.8)    |
| Diabetes                     | 40.1 (3.6)    | 50.4 (7.1)   | 17.2 (2.3)   | 15.2 (3.5)    |
| Cancer                       | 47.8 (8.5)    | 78.3 (13.1)  | 57.6 (17.1)  | 188.4 (20.8)  |
| Traffic                      | 22.3 (3.7)    | 29.4 (6.8)   | 31.9 (8.9)   | 10.4 (1.5)    |
| War/terrorism                | 117.3 (22.4)  | NA           | 0.7 (< 1)    | NA            |

Abbreviations: NA, not applicable or not provided.
5. Majid RA, Mohammed HA, Saeed HM, et al: Breast cancer in Kurdish women of northern Iraq: Incidence, clinical stage, and case control analysis of parity and family risk. BMC Womens Health 9:33, 2009
6. Majid RA, Hassan HA, Muhealdeen DN, et al: Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC Womens Health 17:27, 2017
7. Bray F, Colombero M, Meryl L, et al (eds): Cancer Incidence in five continents, Vol XI (electronic version). Lyon, France, International Agency for Research on Cancer. 2017 http://icr.iarc.fr
8. Cancer Incidence Report, Saudi Arabia 2014. Saudi Cancer Registry, Saudi Health Council Kingdom of Saudi Arabia, September 2017. https://nhic.gov.sa/esServices/Documents/2014.pdf
9. Hovland M, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2014, National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/
10. US Census Bureau: Current population survey, annual social and economic supplement, 2010. www.census.gov/prod/cen2010/doc/sf1.pdf
11. Bray F, Colombet M, Meryl L, et al (eds): Cancer Incidence in the Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Bethesda, MD, National Cancer Institute, NIH publication 06-5973, 2006, pp 131-139
12. Perry AM, Debold J, Nathwani BN, et al: Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica 101:1244-1250, 2016
13. Masters Public Health Curriculum.: Rate ratios-SPH-Boston University. October 16, 2017.http:sphweb.bumc.bu.edu/otit/MPH-Modules/QuantCore/PH717_ComparingFrequences9.html
14. Soliman AS, Botteja P: Lymphoma and leukemia, in Friedman LS, Edwards BK, Ries LAG, et al (eds): Cancer Incidence in the United States, 1973-1977. Atlanta, GA, American Cancer Society, 1983, vol 2, pp 329-342
15. Punjab cm, Nazir M, Manzoor N, et al: Lymphomas in 123 cases from a single geographic region: An immunohistochemical study. Pathol Res Pract 187:511-524, 1991
16. Naresh KN, Agarwal B, Nathwani BN, et al: Use of the World Health Organization (WHO) classification of non-Hodgkin’s lymphoma in Mumbai, India: A review of 200 consecutive cases by a panel of five expert hematopathologists. Leuk Lymphoma 45:1569-1577, 2004
17. Mustafa M, Al Ruhaibeh M, Al Issa A, et al: Lymphoma at King Hussein Medical Center: A histopathologic review. J Royal Medical Services. 20:27-32, 2013
18. International Agency for Research on Cancer: Registry-specific tables, North America. International Incidence of Childhood Cancer 3 (IICC-3). World Health Organization. http://iarc.iarc.fr/registries/registries.pdf
19. Anwar N, Kingma DW, Bloch AR, et al: The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt: Epidemiologic correlations. Cancer 76:1245-1252, 1995
20. Ertem U, Duru F, Pamir A, et al: Burkitt’s lymphoma in 63 Turkish children diagnosed over a 10 year period. Pediatr Hematol Oncol 13:123-134, 1996
21. Kelly GL, Richardson AB: Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematology (Am Soc Hematol Educ Program) 2007:277-284, 2007
22. Flavell KJ, Murray PG: Hodgkin’s disease and the Epstein-Barr virus. Mol Pathol 53:262-269, 2000
23. Fadhil MS, Al-Nueimy WM, Lai WT: Hodgkin’s lymphoma: An immunohistochemical profile in northern Iraq, Saudi Med J 35:448-453, 2014
24. Addassi A.: Hodgkin’s lymphoma in Jordan: A retrospective analysis of 477 cases in King Hussein Cancer Centre. Blood 118:4862, 2011 (abstr)
25. Stein H, Swardlow SH, Gascoyne RD, et al: Nodular lymphocyte predominant Hodgkin’s lymphoma, in Smerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumors of Hematopoietic and Lymphoid Tissue. Lyon, France, International Agency for Research on Cancer, 2016, pp 431-434
26. Huppmann AR, Nicolae A, Stack GW, et al: EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 38:316-324, 2014
27. The World Bank.: Life expectancy at birth. United Nations Population Division, World Population Prospects: 2017 revision. https://data.worldbank.org/indicator/sp.dyn.le00.in
28. World Health Organization.: Global Health Observatory data repository. By Category: NCD deaths by cause and sex. Data by country.apps.who.int/gho/data/node.main.NCDEATHCAUSESNUMBER?lang=en
29. Khoury SA, Massad D, Fardous T: Mortality and causes of death in Jordan 1995-96: Assessment by verbal autopsy. Bull World Health Organ 77:641-650,1999
30. Hooi JKY, Lai WY, Ng WK, et al: Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 153:420-429, 2017
31. Smatti MK, Al-Sadeq DW, Ali NH, et al: Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: An update. Front Oncol 8:211, 2018
32. Ablashi DV, Chatlynne LG, Whitman JE Jr, et al: Spectrum of Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 15:439-464, 2002
33. Tarky AM, Akram W, Al-Naaimi AS, et al: Epidemiology of viral hepatitis B and C in Iraq: A national survey 2005-2006. Zanco J Med Sci. 17:277-284, 2007
34. Flavell KJ, Murray PG: Hodgkin’s disease and the Epstein-Barr virus. Mol Pathol 53:262-269, 2000
35. Fadhil MS, Al-Nueimy WM, Lai WT: Hodgkin’s lymphoma: An immunohistochemical profile in northern Iraq, Saudi Med J 35:448-453, 2014
36. Al-Ajlan A: Prevalence of hepatitis B and C among students of health colleges in Saudi Arabia. East Mediterr Health J 17:759-762, 2011
37. Roberts H, Kruszon-Moran D, Ly KN, et al: Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hapatology 63:388-397, 2016
38. Holmberg SD, Spradling PR, Momcan AG, et al: Hepatitis C in the United States. N Engl J Med 368:1859-1861, 2013
39. Ali AA, Sharif DA, Almukhtar SE, et al: Incidence of glomerulonephritis and non-diabetic end-stage renal disease in a developing middle-east region near armed conflict. BMC Nephrol 19:257, 2018
40. American Cancer Society: Global Cancer Facts and Figures (ed 2). Atlanta, GA, American Cancer Society, 2011